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Abstract
BACKGROUND
Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a
well-established therapeutic target in breast and gastric cancers. While the role of
HER2 as a prognostic biomarker in colorectal adenocarcinomas (CRCs) remains
uncertain, its relevance as a therapeutic target has been established. We
undertook the present study to evaluate the frequency of HER2 expression in
CRC and to correlate it with various clinicopathological variables.
AIM
To correlate HER2 protein expression and HER2 gene amplification with
clinicopathological features and survival in surgically resected CRC.
METHODS
About 1195 consecutive surgically resected CRCs were analyzed by
immunohistochemical staining (IHC) to assess HER2 protein expression, and 141
selected tumors were further evaluated by fluorescence in situ hybridization
(FISH) to assess HER2 gene amplification. Follow-up information was available
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for 1058 patients, and using this information we investigated the prevalence of
HER2 protein overexpression and gene amplification in a large series of
surgically resected CRCs, and evaluated the relationship between overexpression
and clinicopathological parameters and prognosis.
RESULTS
HER2 IHC scores of 3+, 2+, 1+, and 0 were seen in 31 (2.6%), 105 (8.8%), 475
(39.7%), and 584 (48.9%) tumors, respectively. HER2 gene amplification was seen
in 24/29 tumors with an IHC score of 3+ (82.8%; unreadable in 2/31), 12/102
tumors with an IHC score of 2+ (11.8%; unreadable in 2/104), and 0 tumors with
IHC score of 1+ (0/10). HER2 gene amplification was seen in 36/1191 tumors
(3.0%; unreadable in 4/1195). Among the tumors with HER2 IHC scores of 3+
and 2+, the mean percentage of tumor cells with positive IHC staining was 90%
(median 100%, range 40%-100%) and 67% (median 75%, range 5%-95%),
respectively (P < 0.05). Among tumors with IHC scores of 2+, those with HER2
gene amplification had a higher number of tumors cells with positive IHC
staining (n = 12, mean 93%, median 95%, range 90%-95%) than those without (n =
90, mean 70%, median 50%, range 5%-95%) (P < 0.05). HER2 gene status was
significantly associated with distant tumor metastasis and stage (P = 0.028 and
0.025). HER2 protein overexpression as measured by IHC or HER2 gene
amplification as measured by FISH was not associated with overall survival (OS)
or disease-specific survival for the overall group of 1058 patients. However,
further stratification revealed that among patients with tubular adenocarcinomas
who were 65 years old or younger (n = 601), those exhibiting HER2 gene
amplification had a shorter OS than those without (mean: 47.9 mo vs 65.1 mo, P =
0.04). Among those patients with moderately to poorly differentiated tubular
adenocarcinomas, those with positive HER2 tumor IHC scores (2+, 3+) had a
shorter mean OS than those with negative HER2 IHC scores (0, 1+) (47.2 mo vs
64.8 mo, P = 0.033). Moreover, among patients with T2 to T4 stage tumors, those
with positive HER2 IHC scores also had a shorter mean OS than those with
negative HER2 IHC scores (47.1 mo vs 64.8 mo, P = 0.031).
CONCLUSION
HER2 protein levels are correlated with clinical outcomes, and positive HER2
expression as measured by IHC confers a worse prognosis in those patients 65
years old or younger with tubular adenocarcinomas.
Key words: Human epidermal growth factor receptor 2; Immunohistochemical staining;
Fluorescent in situ hybridization; Prognosis; Colorectal cancers
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: The manuscript investigated the prevalence of human epidermal growth factor
receptor 2 (HER2) protein overexpression and gene amplification in a large series of
surgically resected colorectal adenocarcinomas (CRCs), and evaluated their relationship
with clinicopathological parameters and prognosis. We found that HER2 overexpression
[immunohistochemical staining (IHC) score 2+ and 3+] is seen in a small percentage of
colorectal adenocarcinomas and HER2 gene amplification occurs in the vast majority of
tumors with 3+ IHC score but in a much lower percentage of tumors with 2+ IHC score.
In addition, although the prevalence of HER2 overexpression by IHC in CRCs is low,
HER2 protein status is correlated with clinical outcomes and positive HER2 expression
by IHC confers a worse prognosis in 65 years or younger patients with tubular
adenocarcinomas.
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INTRODUCTION
Colorectal  adenocarcinoma (CRC) is  one of  the most  common malignancies  and
remains one of the leading causes of cancer-related death in the world[1]. The vast
majority  of  colorectal  cancers  are  adenocarcinomas.  Until  recently,  the  role  of
chemotherapy in treating CRC has been fairly limited, and as such there is a need to
develop more effective therapeutic regimes for CRC.
Human  epidermal  growth  factor  receptor  2  (HER2)  represents  a  promising
therapeutic target. The HER2 gene is a proto-oncogene located on chromosome 17q21
encoding HER2 (ErbB-2), which is involved in cell proliferation and differentiation[2].
The HER2 protein is a transmembrane receptor tyrosine kinase and a member of the
family of the epidermal growth factor receptors[3].  Oncogenic activation of HER2
commonly occurs through gene amplification, which results in protein overexpression
on the cell membrane that is involved in signal transduction to regulate cell growth[4].
HER2  overexpression/amplification  is  linked  to  trastuzumab  response  in
breast/gastric  cancers.  For  breast  cancer  in  particular,  HER2  serves  as  both  a
prognostic factor and also a therapeutic target, with targeted therapy against HER2
using the monoclonal antibody Trastuzumab (Herceptin) having become the standard
of care for patients whose breast carcinomas exhibit HER2 gene amplification[5-7]. A
recent  randomized  phase  III  trial  (ToGA)  also  revealed  that  the  addition  of
trastuzumab to chemotherapy improved response rates, median progression-free
survival, and overall survival in patients with advanced gastric or gastroesophageal
junction cancer with HER2 overexpression[8].
Compared  to  breast  and  gastric  cancers,  the  data  regarding  HER2  protein
overexpression and gene amplification in CRCs are limited[9-18]. The numbers of cases
in these previous studies were relatively small, and their analyses were primarily
reliant upon tissue microarrays[9-18]. In addition, the reported rates of HER2 protein
overexpression ranged widely from 3% to 47.4% across studies, indicating that the
clinical significance of HER2 in CRC has not yet been fully clarified. In this study, we
assessed  HER2  overexpression  in  1195  CRC  patients  via  immunohistochemical
staining (IHC) in 1195 patients and analyzed HER2 gene status via fluorescence in situ
hybridization (FISH) in a subset of these patients (all tumors with IHC scores of 2+
and 3+, and some a score of 1+). We then correlated HER2 protein overexpression and
HER2 gene status with clinicopathologic features and prognosis to gain insight into
the importance of this marker in the context of CRC.
MATERIALS AND METHODS
Patients and tissue specimens
This  investigation  was  performed  after  approval  was  obtained  from  the  Ethics
Committee of Peking University Cancer Hospital.
A total of 1195 colorectal cancer (545 rectal cancer and 650 colon cancer) patients
who underwent curative surgery between April 2009 and March 2012 in the Peking
University Cancer Hospital and Institute were included in this study. None of these
patients had undergone preoperative radiation or chemotherapy. Clinicopathologic
parameters including age,  gender,  tumor site,  tumor type,  tumor differentiation,
localization and type of the tumor, tumor T stage, lymph node status, and distant
metastasis were retrieved from clinical and pathological databases. Follow-up data
was available  for  a  total  of  1058  CRC patients,  and was  retrieved from hospital
records by interview, telephone, or mailed letters. Follow-up time started on the day
of primary tumor surgical operation. The end point for the disease-associated overall
survival (OS) analysis was the time of death of the patient or our last review. Disease
free survival (DFS) was defined as the time from the date of operation to the date of
diagnosis of metastatic disease or recurrence.
Immunohistochemical analysis
IHC was performed with the Ventana pathway rabbit monoclonal antibody to HER2
(clone 4B5; prediluted) on a Ventana Benchmark automated stainer (Ventana, Tucson,
Arizona) following the manufacturer’s protocol. Antigen retrieval was performed
using Cell Conditioning 1 citrate buffer (pH 6.0; Ventana) for 30 min. Immunostaining
was scored by two pathologists using a 4-step scale (0, 1+, 2+, 3+) according to the
consensus panel recommendations regarding HER2 scoring for gastric cancer[19,20]. The
IHC staining was scored: 0 (no staining or membranous staining in less than 10% of
tumor cells), 1+ (faint/barely visible membranous staining in at least 10% of cells or
staining in parts of their membrane), 2+ (weak to moderate complete or basolateral
membranous  staining  in  at  least  10%  of  tumor  cells),  3+  (strong  complete  or
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basolateral membraneous staining in at least 10% of tumor cells). HER2 IHC scores of
2+ and 3+ were considered as being “HER2 positive”, while IHC scores of 0 and 1+
were considered as being “HER2 negative”.
FISH
FISH was carried out using the PathVysion HER2 DNA probe kit and procedure
(Vysis/Abbott, Abbott Park, Illinois). The kit contains 2 fluorescently labeled DNA
probes,  HER2  (labeled  with  Spectrum-Orange)  and  CEP17  (chromosome  17
enumeration probe labeled with Spectrum-Green). The total numbers of HER2 and
CEP17 signals were counted in at least 20 tumor cell nuclei in 2 different areas. FISH
staining was evaluated by two different investigators to ensure consistency.  The
criteria for positive gene amplification were: a HER2/CEP17 signal ratio of 2.0 or
higher,  or  the  presence  of  tight  gene  clusters  as  previously  reported;  otherwise
samples were defined as being negative for gene amplification[14].
Statistical analysis
All statistical analyses were performed using the SPSS software version 20.0 statistical
package (SPSS Inc.,  Chicago, IL, USA). The correlation between HER2 status and
patient clinicopathological characteristics was tested via the χ2 test or Fisher’s exact
test. Survival curves were fitted using the Kaplan-Meier method, and the differences
in survival were assessed by the log rank test.  The effects of  different factors on
patient survival were assessed via multivariate analysis with the Cox proportional
hazards regression model, and the hazard ratio and associated 95%CI were calculated
for each factor. P-values < 0.05 (two-sided) were considered as being statistically
significant.
RESULTS
Clinicopathological features of colorectal cancer patients
Among these 1195 CRC patients, 718 were males and 477 were females. The patient
ages ranged from 29 to 92 years (mean: 60.8 years). The tumors were staged as pT1 in
32 patients, pT2 in 175 patients, pT3 in 937 patients, and pT4 in 51 patients (Table 1).
Lymph node metastasis was evident in 602 patients (N1 in 296 patients, N2 in 306
patients). Follow-up data was available for a total of 1058 CRC patients, including 640
males and 418 females. These patients ranged in age from 24 to 89 years (mean 61
years).  568  patients  had colon  cancer,  while  490  had rectal  cancer  patients.  The
histopathological diagnosis was tubular adenocarcinoma in 971 (91.8%) patients and
mucinous adenocarcinoma or other types in 87 (8.2%) patients. According to the TNM
classification system, 198 (18.7%) of CRC patients had stage I and II tumors, while 860
(81.3%)  of  patients  had  stage  III  and  IV  disease.  Clinicopathological  data  are
summarized in Table 1.
HER2 protein overexpression by IHC analysis
Among these 1195 CRC tumors, HER2 IHC scores of 3+, 2+, 1+ and 0 were observed
in 31 (2.6%), 105 (8.8%), 475 (39.7%) and 584 (48.9%) tumors, respectively (Table 2,
Figure 1). Among the tumors with IHC 3+ and 2+ scores, the mean percentage of
tumor cells with positive staining was 90% (median 100%, range 40%-100%) and 67%
(median 75%, range 5%-95%), respectively (P < 0.05).
Correlation between HER2 protein overexpression and HER2 gene amplification
All 31 tumors with positive 3+ HER2 staining were further evaluated by FISH to assay
for HER2 gene amplification. The FISH results in 29 tumors (29/31; unreadable in
2/31) were evaluable and 24 (24/29, 83%) showed HER2 gene amplification (Table 3,
Figure 2). HER2 gene amplification was seen in 12/102 (11.8%; unreadable in 2/104)
tumors with HER2 IHC scores of 2+, and 0 (0/10) tumors with IHC scores of 1+ (Table
3, Figure 1). Among the 104 tumors with IHC scores of 2+, those with HER2 gene
amplification had a higher number of tumor cells with positive IHC staining (n = 12;
mean 93%, median 95%, range 90%-95%) than did those without (n = 102; mean 70%,
median 50%, range 5%-95%) (P < 0.05) (Figure 2).
Correlation of HER2 gene status with clinicopathological features
HER2 gene amplification was significantly associated with tumor depth of invasion,
distant metastasis, and stage (P = 0.001, 0.028, and 0.012, respectively; Table 4), while
there was no significant association between HER2 gene status and age, sex, tumor
site, grade, histology, or lymph node metastasis (P > 0.05 for all). And we didn’t find
any observably differences between right/left-sided tumors in this study (P = 0.514).
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Table 1  Clinicopathological features of colorectal cancers
Clinical / pathological features n
Gender
Male 718
Female 477
Age (yr)
≤ 60 578
> 60 617
Tumor grade
G1 42
G2 857
G3 296
Tumor stage
pT1 32
pT2 175
pT3 937
pT4 51
Nodal status
pN0 593
pN1 296
pN2 306
Tumor type
Tubular carcinoma 1089
Mucinous carcinoma 106
Localization
Ascending colon 273
Transverse colon 32
Descending colon 56
Sigmoid 289
Rectum 545
Total number 1195
Correlation of HER2 status with clinical prognosis
A total of 1058 CRC patients with available follow-up data were further assessed for
overall survival. Median OS was 49.35 mo (1.1 to 77.0 mo) and median DFS was 48.80
mo (1.0 to 77.0 mo) for the patients without evidence of metastasis before surgery (n =
941).
Neither HER2 protein overexpression nor HER2 gene amplification were associated
with OS (P = 0.220 and 0.458, respectively; Figure 3A). Tumor grade, histologic type,
lymph node metastasis, and tumor stage were each significantly associated with OS (P
< 0.05 for all; Table 5). Neither HER2 protein overexpression nor HER2 gene status
was associated with DFS (P = 0.320 and 0.662, respectively).
There was no association between HER2 gene amplification and OS or DFS among
the 971 patients with tubular adenocarcinomas, this was not the case among the 797
patients who were 65 years old or younger. Among this group of patients, HER2
protein overexpression was associated with a shorter mean OS for those with tubular
adenocarcinoma (47.1 mo for positive vs  65.1 mo for negative, P  = 0.025, n  = 601;
Figure 2B). In a particular subpopulation of patients, those with moderately to poorly
differentiated tubular adenocarcinomas (n  = 573),  the mean OS in those patients
whose tumors did not exhibit HER2 gene amplification was significantly longer than
those with evidence of HER2 gene amplification (mean: 64.8 mo vs 46.4 mo, P = 0.020;
Figure 2C). Moreover, among the subgroup of patients with stage T2 to T4 tubular
adenocarcinomas (n = 580), those tumors had HER2 gene amplification had a shorter
OS compared to those without HER2 gene amplification (mean: 47.1 mo vs 64.8 mo, P
= 0.031; Figure 2D).
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Figure 1
Figure 1  Immunohistochemical staining of human epidermal growth factor receptor 2. A,B: Immunohistochemical staining of human epidermal growth factor
receptor 2 in most colorectal adenocarcinomas (CRCs) was scored as either 0 (A) or 1+ (B); C: Approximately 9% of CRCs exhibited 2+ staining; D: Only 2.6% of
CRCs exhibited 3+ staining.
DISCUSSION
In this study we assessed HER2 protein overexpression and HER2 gene amplification
in  a  large  series  of  1195  colorectal  adenocarcinomas.  11.4% (136/1195)  of  these
colorectal adenocarcinomas were positive for HER2 staining by IHC (scores of 2+ and
3+). HER2 gene amplification was identified in 11.8% (12/102) of tumors with HER2
IHC scores of 2+ and in 82.8% (24/29) of tumors with HER2 IHC scores of 3+. No
tumors with HER2 IHC scores of 1+ showed evidence of HER2 gene amplification by
FISH. Our findings indicate that  HER2 protein overexpression occurs in a  small
percentage of colorectal adenocarcinomas, similarly to what has been reported in
previous studies. There are only 9 prior studies regarding HER2 status in colorectal
adenocarcinomas in the English literature[9-17]. Three of these nine studies used tissue
microarrays (104, 518, and 1851 patients, respectively) and the remaining 6 used full
tissue blocks (ranging from 138 to 317 patients)[9-17]. Our study is the largest to date to
employ full tumor tissue blocks for analysis (1195 patients). The reported rates of
HER2 protein overexpression in the literature ranged from 2.7% to 15.5%, with the
exception of one study in which the authors reported 47.4% positive HER2 staining in
137 colorectal adenocarcinomas[9-17]. One explanation for this dramatic range in HER2
overexpression positivity across studies may be that antibodies used for staining
varied among research groups. The HER2 antibody used in the study with highest
positive HER2 staining (47.4%) was a polyclonal rabbit antibody. Even though those
authors demonstrated a high HER2 overexpresssion rate, the percentage of cases
exhibiting HER2 gene amplification was only 8% in those with 3+ HER2 staining, and
0% in 38 cases with 2+ HER2 staining, raising questions regarding the validity of the
IHC scoring. The positive rates of HER2 protein staining in studies using the DAKO
HER2 antibody were 2.7% to 15.5%, while it  was 8% in the study using Ventana
pathway antibody by Kavanagh et al[14] and was 11.4% in our study using this same
Ventana pathway.
Our study also indicates that there is a high concordance between HER2 IHC 3+
staining and HER2 gene amplification in colorectal adenocarcinomas. In our study
83% of tumors (24/29) with 3+ HER2 staining exhibited HER2 gene amplification.
There were 6 other studies in the literature on this topic, however the number of cases
analyzed in 5 of these 6 studies was small (less than 10). Marx et al[15] found that 100%
of tumors (27/27) with 3+ HER2 staining (as measured with the DAKO antibody)
harbored HER2 gene amplifications. In the study by Park et al[10], only 2 of 27 tumors
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Table 2  Distribution of human epidermal growth factor receptor 2 staining in 1195 colorectal
adenocarcinomas
Staining pattern Number of cases Positive rate
IHC 3+ 31 2.6%
IHC 2+ 105 8.8%
IHC 1+ 475 39.7%
IHC 0 584 48.9%
IHC: Immunohistochemical staining.
with 3+ HER2 staining showed evidence of HER2 gene amplification, however, as
described above, the IHC staining in that study was performed using a polyclonal
antibody of uncertain reliability. In 3 other smaller studies (2-6 cases with 3+ HER2
staining), this concordance rate with gene amplification was high (100%). Variations
in the antibodies used likely led to differential staining and scoring, contributing to
the  disagreement  in  HER2  gene  amplification  in  tumors  with  3+  HER2  scores.
Nevertheless, these studies, including ours, have shown that HER2 IHC 3+ staining is
highly  predictive  of  HER2  gene amplification in  colorectal  adenocarcinomas.  In
contrast, the percentage of tumors with HER2 IHC 2+ staining showing evidence of
HER2 gene amplification was highly variable. In our study, such amplification was
only evident in 20% of tumors, similar to what has been reported by Kavanagh et al[14]
(2/9 or 22%, using the Ventana Pathway antibody) and Nathanson et al[9] (1/3 or 33%,
using  the  DAKO  antibody).  In  contrast,  Marx  et  al [15]  observed  HER2  gene
amplification in 75% of tumors with HER2 scores of 2+ (using the DAKO antibody).
In the study by Park et al[10], using the Zymed antibody, no gene amplification events
were observed in such tumors. In the study by Ooi et al[11], 2/2 tumors with 2+ HER2
staining  showed evidence  of  HER2  gene  amplification  (using  an  antibody from
Nicheri, Japan). Similarly, variations in the antibodies used likely led to differential
staining and scoring, contributing to the observed high levels of reported variation in
HER2 gene amplification in tumors with 2+ HER2 scores.
The  high  concordance  between  HER2  IHC  3+  staining  and  HER2  gene
amplification indicates that gene amplification is the major factor accounting for
HER2 protein overexpression in colorectal adenocarcinomas with HER2 IHC scores of
3+. However, HER2 gene amplification was seen in only 12/102 (11.8%) tumors with
HER2 IHC scores of 2+, and among these tumors, those with evidence of HER2 gene
amplification had a higher number of tumor cells with positive IHC staining (n = 12,
mean  93%)  than  those  without  (n  =  90,  mean  70%)  (P  <  0.05).  Our  study  thus
confirmed reported results regarding colorectal cancer, and these results were similar
to those observed in breast cancer where IHC 3+ HER2 overexpression is highly
correlated with HER2 gene amplification, whereas 2+ staining is equivocal for gene
amplification[21-24].
In our present study, HER2 gene amplification was higher in patients with a more
advanced disease stage or distant metastases. This suggests that HER2 may play some
role in tumor progression and would thus be a valuable prognostic factor for certain
CRC patients. In our study, the significance of HER2  gene amplification was best
observed in the subpopulation of patients who were 65 years or younger with tubular
adenocarcinomas. However, we did not observe a significant difference in prognosis
for  all  colorectal  carcinoma patients,  regardless  of  HER2 amplification or  HER2
expression status.
Although we found a  statistically  significant  association  between HER2  gene
amplification and tumor depth of invasion, advanced stage, and distant metastasis,
several other studies have failed to show such associations[15,19,25,26].  Those studies,
however, reported a correlation between HER2 gene amplification and high grade
histology, higher tumor stage, and positive nodal status[27,28]. The role of HER2 as a
prognostic factor in CRCs is still controversial, as some of the earlier studies have
failed to identify any specific association with prognosis[28,29] while others reported a
correlation  between  HER2  gene  amplification  and  poorer  survival[30].  Similar
observations have been made for gastric cancer, although a larger number of studies
have supported the association between HER2 overexpression and poorer survival[31].
Possible explanations for such discrepancies include: Antibody resources, detection
methods,  scoring systems, and patient populations (different ethnic groups with
different genetic backgrounds). It  has been clearly demonstrated that HER2  gene
amplification differs significantly between right/left-sided and rectal carcinomas. We
were not able to produce similar results, potentially due to differences in groups
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Figure 2
Figure 2  Fluorescence in situ hybridization results. By fluorescence in situ hybridization, all tested tumors with 1+
human epidermal growth factor receptor 2 (HER2) staining and 80% of tumors with 2+ staining showed no evidence
of HER2 gene amplification (A) whereas 83% of tumors with 3+ HER2 staining harbored HER2 gene amplifications
(B).
analyzed, HER2 testing methods, and tumor biological characteristics[32,33].
In summary, we investigated HER2 protein status and HER2 gene status in a large
series  of  colorectal  adenocarcinomas.  Our  results  show  that  HER2  protein
overexpression is evident in 11.4% of colorectal adenocarcinomas. HER2 IHC scores of
3+ are  highly correlated with HER2  gene amplification,  while  this  correlation is
weaker in tumors with IHC 2+ staining. We also observed an association between
HER2 gene amplification and prognosis in patients with tubular adenocarcinomas
who were 65 years  or  younger.  Our study indicates  that  a  certain population of
patients with colorectal adenocarcinomas may benefit with HER2-targeted therapy.
WJGO https://www.wjgnet.com April 15, 2019 Volume 11 Issue 4
Wang XY et al. HER2 in colorectal adenocarcinomas
342
Table 3  Concordance between human epidermal growth factor receptor 2 overexpression by Immunohistochemical staining and human
epidermal growth factor receptor 2 gene amplification by fluorescence in situ hybridization
IHC score
HER2 gene amplification (FISH) % HER2 gene
amplificationPositive Negative
1+ (n = 10) 0 10 0%
2+ (n = 102) 12 90 11.8%
3+ (n = 29) 24 5 82.8%
HER2: Human epidermal growth factor receptor 2; FISH: Fluorescence in situ hybridization; IHC: Immunohistochemical staining.
Table 4  Association of human epidermal growth factor receptor 2 gene status with clinicopathological features n (%)
Clinicopathological features
HER2 status
P-value
HER2 negative HER2 positive
Gender 0.441
Male 616 (96.2) 24 (3.8)
Female 406 (97.1) 12 (2.9)
Age (yr) 0.272
≤ 60 501 (96.0) 21 (4.0)
> 60 521 (97.2) 15 (2.8)
Tumor grade 0.784
1 39 (97.5) 1 (2.5)
2 773 (96.7) 26 (3.3)
3 210 (95.9) 9 (4.1)
Histology 0.762
Tubular 937 (96.5) 34 (3.5)
Mucinous/other types 85 (97.7) 2 (2.3)
Tumor site 0.819
Colon 548 (96.5) 20 (3.5)
Rectal 474 (96.7) 16 (3.3)
Left-sided colon 203 (88.3) 27 (37.0) 0.514
Right-sided colon 292 (86.4) 46 (63.0)
Depth of invasion
T1 31 (100.0) 0 (0.0) 0.039
T2 165 (98.8) 2 (1.2)
T3 815 (96.3) 31 (3.7)
T4 11 (78.6) 3 (21.4)
T1-2 196 (99.0) 2 (1.0) 0.001
T3-4 826 (96.0) 34 (4.0)
Lymph node metastasis
N0 541 (96.3) 21 (3.7) 0.260
N1 261 (98.1) 5 (1.9)
N2 220 (95.7) 10 (4.3)
No 541 (96.3) 21 (3.7) 0.524
Yes 481 (97.0) 15 (3.0)
Distant metastasis 0.028
No 940 (96.9) 30 (3.1)
Yes 81 (92.0) 7 (8.0)
Tumor stage
(1)I-II 192 (98.5) 2 (1.0) 0.012
III 749 (96.5) 27 (3.5)
IV 81 (92.0) 7 (8.0)
(3)I-II 192 (99.0) 2 (1.0) 0.044
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III-IV 830 (96.1) 34 (3.9)
HER2: Human epidermal growth factor receptor 2.
Table 5  Overall survival based on clinicopathological features
Clinicopathological features Patients Events Median survival (95%CI), mo P-value
Gender 0.707
Male 640 144 NA
Female 418 100 NA
Age (yr)
≤ 60 522 116 NA 0.591
> 60 536 128 NA
≤ 65 661 138 NA 0.027
> 65 397 106 NA
Tumor site 0.457
Colon 568 133 NA
Rectal 490 111 NA
Tumor grade 0.000
1-2 839 176 NA
3 219 68 NA
Histology 0.000
Tubular 971 205 NA
Mucinous/ Other types 87 39 54.90
Lymph node metastasis 0.000
No 562 61 NA
Yes 496 183 NA
Tumor stage 0.000
I-II 198 13 NA
III-IV 860 231 NA
HER2 protein overexpression by IHC
IHC (-) 935 221 NA 0.220
IHC (+) 123 23 NA
HER2 gene amplification by FISH
Positive 1022 234 NA 0.458
Negative 36 10 NA
NA: Because the overall survival rates of these patients were more than 50%, we didn’t get the median survival time. HER2: Human epidermal growth
factor receptor 2; FISH: Fluorescence in situ hybridization; IHC: Immunohistochemical staining.
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Figure 3
Figure 3  Kaplan-Meier overall survival analysis. A: Kaplan-Meier overall survival (OS) analysis of colorectal adenocarcinoma patients based on human epidermal
growth factor receptor 2 (HER2) expression status (as determined by fluorescence in situ hybridization); B: Kaplan-Meier OS analysis of tubular adenocarcinoma
patients age ≤ 65 based on HER2 expression status; C: Kaplan-Meier OS analysis of tubular adenocarcinoma patients with moderate-poor differentiation and age ≤
65 based on HER2 expression status; D: Kaplan-Meier overall survival analysis of tubular adenocarcinoma patients with stage T2-4 tumors and age ≤ 65 based on
HER2 expression status. HER2: Human epidermal growth factor receptor 2; FISH: Fluorescence in situ hybridization.
ARTICLE HIGHLIGHTS
Research background
The  vast  majority  of  colorectal  cancers  are  adenocarcinomas.  Until  recently,  the  role  of
chemotherapy in treating colorectal adenocarcinomas (CRCs) has been fairly limited, and as such
there is a need to develop more effective therapeutic regimes for CRC. Human epidermal growth
factor receptor 2 (HER2) is an oncogenic driver; it’s a well-established therapeutic target in breast
and gastric cancers.
Research motivation
The role of HER2 as a prognostic biomarker in CRCs remains uncertain, but its relevance as a
therapeutic target has been established.
Research objectives
In this study, the authors aim to evaluate the frequency of HER2 expression in CRC and to
correlate it with various clinicopathological variables.
Research methods
In this study, to assess HER2 protein expression, 1195 consecutive surgically resected CRCs were
analyzed by immunohistochemical staining (IHC). And to assess HER2 gene amplification, 141
selected tumors were further evaluated by fluorescence in situ hybridization (FISH). The authors
investigated the prevalence of HER2 protein overexpression and gene amplification in a large
series of surgically resected CRCs, and evaluated the relationship between overexpression and
clinicopathological parameters and prognosis.
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Research results
HER2 gene amplification was seen in 24/29 tumors with an IHC score of 3+, 12/102 tumors with
an IHC score of 2+, and 0 tumors with IHC score of 1+ (0/10). HER2 gene amplification was seen
in 36/1191 tumors. Among the tumors with HER2 IHC scores of 3+ and 2+, the mean percentage
of tumor cells with positive IHC staining was 90% and 67%. Among tumors with IHC scores of
2+, those with HER2 gene amplification had a higher number of tumors cells with positive IHC
staining than those without. HER2 gene status was significantly associated with distant tumor
metastasis  and  stage.  HER2  protein  overexpression  as  measured  by  IHC  or  HER2  gene
amplification as measured by FISH was not associated with overall survival (OS) or disease-
specific survival for the overall group of 1058 patients. Among those patients with moderately to
poorly differentiated tubular adenocarcinomas, those with positive HER2 tumor IHC scores (2+,
3+) had a shorter mean OS than those with negative HER2 IHC scores (0, 1+).
Research conclusions
HER2 protein levels are correlated with clinical outcomes, and positive HER2 expression confers
a worse prognosis in patients 65 years old or younger with tubular adenocarcinomas.
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